Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 2.42 +0.09 (3.86%)
price chart
Stock Technical Report on Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $2.48, up by 6.44%, with a volume of 911,392 shares against an average volume for the last 3 months of ...
Stocks in News: Immunomedics Inc. (NASDAQ:IMMU), Sunesis Pharmaceuticals ...  Stock Transcript
Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS)
Despite a decrease in cash flow of 20.20%, SUNESIS PHARMACEUTICALS INC is in line with the industry average cash flow growth rate of -24.34%.
Related articles »  
BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will ...
BTIG initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) Monday with a Buy rating and $5.50 price target.
Related articles »  
Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 9% on the day.
Related articles »  
Friday's Gainers In the Spotlight - Tetraphase Pharmaceuticals Inc (NASDAQ ...
Sunesis Pharmaceuticals, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Is This the Sunesis Resurrection?
In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately had catastrophic results for the stock price ...
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of ...
Related articles »  
Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and ...
SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2015.
Roth Capital Cuts Sunesis Pharmaceuticals Price Target to $4.00 (SNSS)  Dakota Financial News
Sunesis Pharmaceuticals' (SNSS) CEO Dan Swisher on Q1 2015 Results ...  Seeking Alpha
Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth
Sunesis Pharmaceuticals, Inc.'s (NASDAQ: SNSS) failed cancer drug vosaroxin offers no reason for investors to give up hope on other companies' potential cures, an analyst said Tuesday.
Qinprezo Phase 3 trial fails (SNSS)  Seeking Alpha (registration)
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin ...  MarketWatch
Related articles »  
UPDATE: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals (SNSS) to Buy ...
Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) gained Wednesday after being upgraded to Buy from Hold with a price target of $4 (from $2) by analyst Mara Goldstein of Cantor Fitzgerald.
3 Buzzing Pharma Stocks: Second Sight Medical Products Inc (EYES), Sunesis ...  NIS
Related articles »  
Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th ...
Sunesis Pharmaceuticals, Inc. SNSS, -2.92% today announced that two poster presentations describing results from the VALOR trial will be presented at the 20th Congress of the European Hematology Association (EHA) being held June 11 - 14, 2015, at the ...